Genome Signature (HRD) Test
Also known as: HRD Genomic Signature, Genomic Instability Score (GIS), HRD Score Test
Genome Signature (HRD) Test test available at DNA Labs India for ₹270,000. Uses Next-Generation Sequencing (NGS), Genomic Instability Score (GIS) analysis on Tumor tissue (paraffin-embedded block) + Peripheral Blood samples. Results in Reports are typically available within 3-4 weeks after the samples are received by the laboratory.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SHAILAJA RAGHUNATH MURDESHWAR
Consultant Physician · Reg: 8052
Last reviewed: September 7, 2026
Overview
The primary purpose of Genome Signature (HRD) testing is to detect homologous recombination deficiency in tumor cells. This information is crucial for oncologists to decide on the use of PARP inhibitors (e.g., olaparib, niraparib) and platinum-based chemotherapy, which are particularly effective in HRD-positive tumors. The test also aids in assessing prognosis and risk stratification for patients with breast, ovarian, and prostate cancers.
- Test Code
- 6105
- CPT Code
- 81479
- ICD Code
- Z12.9
- Price
- ₹270,000
- Sample Type
- Tumor tissue (paraffin-embedded block) + Peripheral Blood
- Result Time
- Reports are typically available within 3-4 weeks after the samples are received by the laboratory.
- Fasting Required
- No
- Method
- Next-Generation Sequencing (NGS), Genomic Instability Score (GIS) analysis
Sample Collection
No special preparation is required. However, a doctor's prescription is mandatory. Inform your doctor about any medications you are taking, especially anticoagulants, as they may affect blood collection.
Method: Biopsy (tumor tissue) and venipuncture (blood)
Laboratory Analysis
Tumor tissue sample is obtained via biopsy (surgical or core needle). Blood samples are drawn from a vein in the arm. The procedure is quick and minimally invasive.
Report Delivery
You may resume normal activities immediately. There may be minor bruising at the blood draw site, which is normal. The tumor tissue sample will be sent to the laboratory for analysis.
Timeline: Reports are typically available within 3-4 weeks after the samples are received by the laboratory.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of Genome Signature (HRD) testing is to detect homologous recombination deficiency in tumor cells. This information is crucial for oncologists to decide on the use of PARP inhibitors (e.g., olaparib, niraparib) and platinum-based chemotherapy, which are particularly effective in HRD-positive tumors. The test also aids in assessing prognosis and risk stratification for patients with breast, ovarian, and prostate cancers.
How to Prepare
- Tumor tissue: Formalin-fixed paraffin-embedded (FFPE) block or unstained slides (minimum 5 slides) with ≥20% tumor cellularity
- Blood: 2 mL in EDTA vacutainer for germline comparison
- Blood: 2 mL in Streck tube for cell-free DNA analysis (if applicable)
- Samples must be labeled with patient name, date of birth, and collection date
- Samples should be transported at room temperature for FFPE blocks and at 2-8°C for blood tubes
Doctor's Notes
Reviewed by Dr SHAILAJA RAGHUNATH MURDESHWAR — MBBS, MD (General Medicine) · Reg. No. 8052
"Genome Signature (HRD) testing is a critical tool for identifying patients with homologous recombination deficiency, which can guide the use of PARP inhibitors and platinum-based therapies. This test provides actionable genomic information that can significantly impact treatment decisions in breast, ovarian, and prostate cancers."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Inadequate tumor tissue (low cellularity)
- Hemolyzed blood samples
- Clotted blood samples
- Improperly labeled samples
- Samples received after prolonged transit time without proper storage
Understanding Your Results
HRD-positive (GIS ≥42 or presence of pathogenic BRCA1/2 mutation)
Likely to benefit from PARP inhibitors (e.g., olaparib) and platinum-based chemotherapy. Consider targeted therapy options.
HRD-negative (GIS <42 and no pathogenic HRR gene mutations)
Less likely to respond to PARP inhibitors; alternative treatment strategies may be considered.
Variant of Uncertain Significance (VUS) in HRR genes
Clinical significance is unclear; further genetic counseling and testing may be recommended.
Consult your oncologist if you have been diagnosed with breast, ovarian, or prostate cancer and are considering targeted therapy options. Also, consult if you have a family history of these cancers and wish to assess your genetic risk.
Limitations
- ⚠Test may not detect all HRD-related genomic alterations
- ⚠Results are dependent on tumor tissue quality and quantity
- ⚠Not a substitute for germline BRCA testing; separate blood-based test may be needed
- ⚠Interpretation requires expert molecular pathologist review
- ⚠Clinical utility may vary based on cancer type and stage
Risks & Considerations
- ●Minor bleeding or bruising at the blood draw site
- ●Infection or bleeding at the biopsy site (rare)
- ●Psychological distress from genetic results
- ●Potential for incidental findings
Interfering Factors
- ●Inadequate tumor tissue sample (low tumor cellularity)
- ●DNA degradation due to improper tissue fixation or storage
- ●Recent chemotherapy or radiation therapy may affect tumor DNA quality
- ●Contamination of tumor sample with normal tissue
- ●Presence of germline variants that may confound somatic analysis
Compare With Similar Tests
| Test | Genome Signature (HRD) | BRCA1/2 Mutation Analysis | Homologous Recombination Repair (HRR) Gene Panel | FoundationOne CDx |
|---|---|---|---|---|
| Comparison | Genome Signature (HRD) |
Frequently Asked Questions
What is the cost of Genome Signature (HRD) testing in India?
What is the sample type required for the Genome Signature (HRD) test?
Is fasting required before the Genome Signature (HRD) test?
How long does it take to get the results of the Genome Signature (HRD) test?
What is the purpose of the Genome Signature (HRD) test?
Is a doctor's prescription required for the Genome Signature (HRD) test?
What is the Genomic Instability Score (GIS) in HRD testing?
Can the Genome Signature (HRD) test be done at home?
Which cancers are associated with HRD?
What is the difference between HRD testing and BRCA testing?
Are there any risks associated with the Genome Signature (HRD) test?
Is the Genome Signature (HRD) test covered by insurance?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.